AGOURA HILLS, Calif.--(

加利福尼亚州阿古拉山。--（

BUSINESS WIRE

商业热线

)--A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the closing of its $80 million Series C financing round, supported by a syndicate of investors that includes The Column Group and Samsara BioCapital.

)--A2 Biotherapeutics，Inc.（A2 Bio）是一家临床阶段细胞治疗公司，开发一流的逻辑门控细胞疗法，以选择性靶向肿瘤细胞并保护正常细胞，今天宣布结束其8000万美元的C系列融资回合，由包括Column Group和Samsara BioCapital在内的投资者财团支持。

Proceeds will fund the company’s three clinical development programs and advancement of its pipeline of CAR-T cell therapies based on its proprietary Tmod™ platform technology..

收益将用于资助该公司的三个临床开发项目，以及基于其专有Tmod™平台技术的CAR-T细胞疗法管道的推进。

“

“

We are excited by the initial clinical data from our lead programs, which we believe validates our proprietary logic-gate technology approach to solid tumor cancers,” said Jim Robinson, chief executive officer of A2 Bio. “

A2 Bio首席执行官吉姆·罗宾逊（JimRobinson）表示：“我们对领先项目的初步临床数据感到兴奋，我们认为这些数据验证了我们专有的逻辑门技术治疗实体瘤癌症的方法。”

This funding will enable us to continue ongoing clinical development of our CAR-T cell therapies as well as fund the potential next phase of development.”

这笔资金将使我们能够继续进行CAR-T细胞疗法的临床开发，并为潜在的下一阶段开发提供资金。”

A2 Bio is currently conducting two seamless phase 1/2 clinical studies: EVEREST-1 studying A2B530 for pancreatic, lung and colorectal cancers by targeting carcinoembryonic antigen (CEA); and EVEREST-2 studying A2B694 for pancreatic, ovarian, lung, colorectal and mesothelioma cancers by targeting mesothelin (MSLN).

A2 Bio目前正在进行两项无缝的1/2期临床研究：EVEREST-1通过靶向癌胚抗原（CEA）研究A2B530治疗胰腺癌，肺癌和结直肠癌；和EVEREST-2通过靶向间皮素（MSLN）研究A2B694治疗胰腺癌，卵巢癌，肺癌，结直肠癌和间皮瘤癌。

Patients are enrolled in EVEREST-1 and EVEREST-2 through the BASECAMP-1 prescreening study. BASECAMP-1 utilizes artificial intelligence (AI)-enabled precision diagnostics, as a cost-effective, high-yield approach to identify eligible patients for all A2 Bio clinical studies..

通过BASECAMP-1预筛选研究，患者被纳入EVEREST-1和EVEREST-2。BASECAMP-1利用人工智能（AI）实现的精确诊断，作为一种经济高效的高产方法，可以为所有A2生物临床研究确定符合条件的患者。。

1

1

A2 Biotherapeutics, established in 2018, is a fully integrated discovery, development and manufacturing company based in Agoura Hills, Calif. A2 Bio plans to direct the Series C funds to support the company’s three clinical studies, as well as to advance preclinical programs using its Tmod™ platform for potential clinical targets representing significant unmet needs in cancer and beyond..

。。

About the Tmod™ Platform

关于Tmod™平台

A2 Bio has pioneered a precision-targeting cellular system – the Tmod™ platform – that incorporates two receptors, an activator and a blocker, to aim the powerful armaments of immune cells directly at tumors to unequivocally differentiate tumors from normal tissues. The activator recognizes antigens on tumor cells that trigger their destruction, while the blocker recognizes antigens on normal cells that protect them.

A2 Bio开创了一种精确靶向细胞系统（Tmod™平台），它包含两种受体，一种激活剂和一种阻断剂，将强大的免疫细胞武器直接瞄准肿瘤，以明确区分肿瘤和正常组织。激活剂识别肿瘤细胞上引发其破坏的抗原，而阻断剂识别正常细胞上保护它们的抗原。

This novel blocker technology enables precise, personalized and effective T cell targeting. The blocker component equips Tmod™ cells with the capacity to identify tumors as distinct from normal cells..

这种新型阻滞剂技术可以实现精确，个性化和有效的T细胞靶向。阻滞剂成分使Tmod™细胞具有识别肿瘤与正常细胞不同的能力。

About A2 Bio

关于A2生物

A2 Biotherapeutics, Inc. (A2 Bio) is a clinical-stage biotech company developing first-in-class logic-gated cell therapies to address the high unmet need in cancers. A2 Bio invented the proprietary Tmod™ cell therapy platform to tackle the fundamental challenge in cancer treatment—the ability of cancer medicines to distinguish between tumor and normal cells.

A2 Biotherapeutics，Inc.（A2 Bio）是一家临床阶段的生物技术公司，开发一流的逻辑门控细胞疗法，以解决癌症中高度未满足的需求。A2 Bio发明了专有的Tmod™细胞治疗平台，以应对癌症治疗的根本挑战-癌症药物区分肿瘤细胞和正常细胞的能力。

For more information, please visit the company’s website at .

欲了解更多信息，请访问公司网站：。

www.a2bio.com

www.a2bio.com

References

参考文献

Lozac’hmeur A, Danek T, Yang Q, Rosasco MG, Welch JS, Go WY, Ng EW, Mardiros A, Maloney DG, Garon EB, Kirtane K, Simeone DM, Molina JR, Salahudeen AA, Stein MM, Hecht JR. Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities.

Lozac'hmeur A，Danek T，Yang Q，Rosasco MG，Welch JS，Go WY，Ng EW，Mardiros A，Maloney DG，Garon EB，Kirtane K，Simeone DM，Molina JR，Salahudeen AA，Stein MM，Hecht JR.在标准诊断测序工作流程中检测HLA杂合性丢失，以获得预后和治疗机会。

NPJ Precis Oncol. 2024 Aug 5;8(1):174. doi: 10.1038/s41698-024-00665-z. PMID: 39103508; PMCID: PMC11300791..

NPJ Precis Oncol。2024年8月5日；8(1):174.doi:10.1038/41698-024-00665-z。项目编号：3910308；PMCID:PMC11300791。